(Q52892914)

9 May 2018

title

Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours. (English)

1 reference

9 May 2018

1 reference

Martin H Maurer

9

0 references

Bernd Hamm

8

object named as

Bernd Hamm

1 reference

9 May 2018

Nils F Schreiter

1

1 reference

9 May 2018

Winfried Brenner

2

1 reference

9 May 2018

Munenobu Nogami

3

1 reference

9 May 2018

Ralph Buchert

4

1 reference

9 May 2018

Alexander Huppertz

5

1 reference

9 May 2018

Ulrich-Frank Pape

6

1 reference

9 May 2018

Vikas Prasad

7

1 reference

9 May 2018

publication date

17 September 2011

1 reference

9 May 2018

European Journal of Nuclear Medicine and Molecular Imaging

published in

1 reference

9 May 2018

volume

39

1 reference

9 May 2018

issue

1

1 reference

9 May 2018

page(s)

72-82

1 reference

9 May 2018

https://scigraph.springernature.com/pub.10.1007/s00259-011-1935-5

exact match

0 references

cites work

A 5-decade analysis of 13,715 carcinoid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1935-5

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1935-5

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1935-5

111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1935-5

Evaluation of Positron Emission Tomography Imaging Using [68Ga]-DOTA-D Phe1-Tyr3-Octreotide in Comparison to [111In]-DTPAOC SPECT. First Results in Patients with Neuroendocrine Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1935-5

Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1935-5

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1935-5

Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1935-5

Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1935-5

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1935-5

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1935-5

[Cost considerations for whole-body MRI and PET/CT as part of oncologic staging].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1935-5

Whole-body MRI and PET-CT in the management of cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1935-5

Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1935-5

Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1935-5

68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with ¹¹¹In-DTPA-octreotide (OctreoScan®).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1935-5

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1935-5

Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide

21 January 2018

1 reference

12 December 2020

The present and future role of (111)In pentetreotide in the PET era.

1 reference

12 December 2020

Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide

1 reference

12 December 2020

Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy

1 reference

12 December 2020

Yttrium-90-labelled somatostatin-analogue for cancer treatment

1 reference

12 December 2020

[Process management and controlling in diagnostic radiology in the hospital]

1 reference

12 December 2020

Processing of generator-produced 68Ga for medical application.

1 reference

12 December 2020

Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin

1 reference

12 December 2020

[Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations].

1 reference

12 December 2020

Gallium-67/gallium-68-[DFO]-octreotide--a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies

1 reference

12 December 2020

10.1007/S00259-011-1935-5

Identifiers

DOI

1 reference

9 May 2018

PubMed ID

21927931

1 reference

9 May 2018